Abstract 13907: Patients With NSTEMI Are at Higher Risk, Have Worse Outcomes, but Less Intense Cardiology Follow-up 1-3 Years Post-discharge: Findings From the TIGRIS Registry
Sibi N Krishnamurthy(University of Miami), Mauricio G. Cohen(Cleveland Clinic Florida), Christopher B. Granger(Clinical Research Institute), Satoshi Yasuda(Tohoku University), Stuart Pocock(London School of Hygiene & Tropical Medicine), Gunnar Brandrup‐Wognsen(AstraZeneca (Sweden)), David Brieger(The University of Sydney), José Carlos Nicolau(Hospital São Paulo), Shaun G. Goodman(University of Toronto), Prashant Kaul(Piedmont Atlanta Hospital), Dirk Westermann(University Medical Center Freiburg), Phillip R. Hunt(AstraZeneca (United States)), Tabassome Simon(Sorbonne Université), Jiyan Chen(Qingdao University of Science and Technology), Karolina Andersson-Sundell(AstraZeneca (Sweden)), Ruth Owen(Spanish National Centre for Cardiovascular Research)
Cited by 0
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k